Holen Sie sich die Stockscreener-App
14.13
1.33%
-0.195
Schlusskurs vom Vortag:
$14.33
Offen:
$14.59
24-Stunden-Volumen:
505.09K
Relative Volume:
0.50
Marktkapitalisierung:
$765.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-695.98M
KGV:
-0.043
EPS:
-328.6331
Netto-Cashflow:
$-143.65M
1W Leistung:
+0.07%
1M Leistung:
+2.39%
6M Leistung:
+77.86%
1J Leistung:
+300.34%
1-Tages-Spanne:
$14.04
$14.65
1-Wochen-Bereich:
$14.04
$15.61
52-Wochen-Spanne:
$3.304
$65.80
Vor Biopharma Inc Stock (VOR) Company Profile
Firmenname
Vor Biopharma Inc
Sektor
Branche
Telefon
617-655-6580
Adresse
500 BOYLSTON STREET, BOSTON
Compare VOR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
14.12 | 776.48M | 0 | -695.98M | -143.65M | -328.63 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.47 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.68 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.20 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.71 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-30 | Eingeleitet | Jefferies | Buy |
| 2026-03-19 | Eingeleitet | Wells Fargo | Overweight |
| 2026-01-09 | Eingeleitet | Citigroup | Buy |
| 2025-12-17 | Eingeleitet | TD Cowen | Buy |
| 2025-12-09 | Eingeleitet | JP Morgan | Overweight |
| 2025-11-25 | Fortgesetzt | Wedbush | Neutral |
| 2025-10-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-09-24 | Hochstufung | Stifel | Hold → Buy |
| 2025-06-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-07-26 | Eingeleitet | Wedbush | Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Neutral |
| 2021-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-12-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-25 | Eingeleitet | B. Riley Securities | Buy |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-03-03 | Eingeleitet | Evercore ISI | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Sell |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
Alle ansehen
Vor Biopharma Inc Aktie (VOR) Neueste Nachrichten
VOR Stock Price, Quote & Chart | VOR BIOPHARMA INC (NASDAQ:VOR) - ChartMill
VOR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $31 - GuruFocus
H.C. Wainwright Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Vor Biopharma Price Target Maintained With a $31.00/Share by HC Wainwright & Co. - Moomoo
Vor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune Therapy - MSN
Vor Biopharma Inc.Common Stock (NQ: VOR - FinancialContent
Venrock group holds capped 9.99% stake in VOR (VOR) via pre-funded warrants - Stock Titan
Verve Capital amends position; holds 9.3% of VOR (NASDAQ: VOR) - Stock Titan
We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate - Moomoo
We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely - Yahoo Finance
Vor Biopharma: Enrollment on Track for Phase 3 UPSTREAM MG Trial of Telitacicept in Generalized Myasthenia Gravis Patients With Topline Results Anticipated in 1H27 >VOR - Moomoo
VOR Maintained by Wedbush -- Price Target Raised to $18.00 - GuruFocus
Wells Fargo Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Vor Biopharma Inc. Q1 2026 Financial Results and Forward-Looking Statements – SEC 10-Q Report - Minichart
Vor Bio Q1 Net Loss Narrows - Moomoo
Earnings Flash (VOR) Vor Biopharma Posts Q1 Net Loss $5.11 a Share, vs. FactSet Est of $0.78 Loss - marketscreener.com
Vor Biopharma Inc. 1Q 2026: Net loss $(219.6M), Diluted EPS $(5.11) — 10-Q Summary - TradingView
Vor Biopharma Q1 net loss widens - TradingView
Vor Biopharma (NASDAQ: VOR) Q1 2026 loss widens as telitacicept trials advance on $491.5M cash runway - Stock Titan
Vor Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
TradingKey - TradingKey
MSN Money - MSN
Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade - MSN
Vor Biopharma Advances Phase 3 Telitacicept Trial in Myasthenia Gravis, Keeping Investor Focus High - TipRanks
[EFFECT] Vor Biopharma Inc. SEC Filing - Stock Titan
Qiming entities report stakes in VOR BioPharma (NASDAQ: VOR) on Schedule 13G/A - Stock Titan
FMR LLC reports 1.54M-share stake in VOR Biopharma (NASDAQ: VOR) - Stock Titan
VOR shares rally over 40% in pre-market trade after JPMorgan initiates bullish coverage - MSN
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Six new Vor Bio hires get stock awards priced at $13.85 - Stock Titan
Jefferies Financial Group Upgrades Vor Biopharma (NASDAQ:VOR) to Strong-Buy - MarketBeat
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Down 17.3% in April - MarketBeat
Vor Biopharma (NASDAQ: VOR) files resale registration for 5.34M shares - Stock Titan
Vor Biopharma (NASDAQ: VOR) plans virtual 2026 meeting and equity plan changes - Stock Titan
[ARS] Vor Biopharma Inc. SEC Filing - Stock Titan
Wall Street analysts predict a 107.82% upside in Vor Biopharma (VOR): Here's what you should know - MSN
Vor Bio announces $75M private placement - MSN
Vor Biopharma (NASDAQ:VOR) Director Ra Capital Management, L.P. Sells 165,150 Shares - MarketBeat
Ra capital healthcare fund sells 165,150 Vor Biopharma shares for $2.6m By Investing.com - Investing.com Australia
Ra capital healthcare fund sells 165,150 Vor Biopharma shares for $2.6m - Investing.com UK
Finanzdaten der Vor Biopharma Inc-Aktie (VOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vor Biopharma Inc-Aktie (VOR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 17 '26 |
Sale |
16.28 |
458,411 |
7,462,931 |
2,739,208 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 20 '26 |
Sale |
15.77 |
171,963 |
2,711,857 |
2,567,245 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 13 '26 |
Sale |
16.15 |
530,610 |
8,569,352 |
3,404,998 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 14 '26 |
Sale |
15.97 |
153,735 |
2,455,148 |
3,251,263 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 15 '26 |
Sale |
16.01 |
53,644 |
858,840 |
3,197,619 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 08 '26 |
Sale |
16.48 |
484,104 |
7,977,786 |
4,071,637 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 09 '26 |
Sale |
16.59 |
135,201 |
2,242,985 |
3,936,436 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 10 '26 |
Sale |
15.75 |
828 |
13,041 |
3,935,608 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 06 '26 |
Sale |
16.59 |
589,257 |
9,777,898 |
4,555,741 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 02 '26 |
Sale |
18.23 |
260,000 |
4,741,066 |
5,144,998 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):